2aqu
From Proteopedia
Line 1: | Line 1: | ||
[[Image:2aqu.gif|left|200px]] | [[Image:2aqu.gif|left|200px]] | ||
- | + | <!-- | |
- | + | The line below this paragraph, containing "STRUCTURE_2aqu", creates the "Structure Box" on the page. | |
- | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
- | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
- | + | or leave the SCENE parameter empty for the default display. | |
- | | | + | --> |
- | | | + | {{STRUCTURE_2aqu| PDB=2aqu | SCENE= }} |
- | + | ||
- | + | ||
- | }} | + | |
'''Structure of HIV-1 protease bound to atazanavir''' | '''Structure of HIV-1 protease bound to atazanavir''' | ||
Line 38: | Line 35: | ||
[[Category: Nukoolkarn, S.]] | [[Category: Nukoolkarn, S.]] | ||
[[Category: Thiaville, M M.]] | [[Category: Thiaville, M M.]] | ||
- | [[Category: | + | [[Category: Aid]] |
- | [[Category: | + | [[Category: Aspartyl protease]] |
- | [[Category: | + | [[Category: Hydrolase]] |
- | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 19:21:45 2008'' | |
- | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + |
Revision as of 16:21, 3 May 2008
Structure of HIV-1 protease bound to atazanavir
Overview
A series of HIV-1 protease mutants has been designed in an effort to analyze the contribution to drug resistance provided by natural polymorphisms as well as therapy-selective (active and non-active site) mutations in the HIV-1 CRF_01 A/E (AE) protease when compared to that of the subtype B (B) protease. Kinetic analysis of these variants using chromogenic substrates showed differences in substrate specificity between pretherapy B and AE proteases. Inhibition analysis with ritonavir, indinavir, nelfinavir, amprenavir, saquinavir, lopinavir, and atazanavir revealed that the natural polymorphisms found in A/E can influence inhibitor resistance. It was also apparent that a high level of resistance in the A/E protease, as with B protease, is due to it aquiring a combination of active site and non-active site mutations. Structural analysis of atazanavir bound to a pretherapy B protease showed that the ability of atazanavir to maintain its binding affinity for variants containing some resistance mutations is due to its unique interactions with flap residues. This structure also explains why the I50L and I84V mutations are important in decreasing the binding affinity of atazanavir.
About this Structure
2AQU is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.
Reference
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir., Clemente JC, Coman RM, Thiaville MM, Janka LK, Jeung JA, Nukoolkarn S, Govindasamy L, Agbandje-McKenna M, McKenna R, Leelamanit W, Goodenow MM, Dunn BM, Biochemistry. 2006 May 2;45(17):5468-77. PMID:16634628 Page seeded by OCA on Sat May 3 19:21:45 2008
Categories: HIV-1 retropepsin | Human immunodeficiency virus 1 | Single protein | Agbandje-McKenna, M. | Clemente, J C. | Coman, R M. | Dunn, B M. | Goodenow, M M. | Govindasamy, L. | Janka, L K. | Jeung, J A. | Leelamanit, W. | McKenna, R. | Nukoolkarn, S. | Thiaville, M M. | Aid | Aspartyl protease | Hydrolase